Horizon Health Network

Canada Launches First Home-Based Cancer Immunotherapy Trial Using Subcutaneous Injection

- Horizon Health Network and Roche Canada have launched the first Canadian trial delivering cancer immunotherapy through subcutaneous injection in patients' homes, marking a significant shift from hospital-based intravenous treatments. - The STITCH-01 study reduces treatment time from 30-60 minutes to approximately seven minutes, offering lung cancer patients a more convenient and less invasive option administered by home care nurses. - This innovative approach aims to reduce healthcare system strain while improving patient quality of life by eliminating travel requirements and minimizing disruptions to daily activities. - The initiative represents a potential model for transforming cancer care delivery across Canada, with expected benefits including reduced hospital resource utilization and lower overall treatment costs.